TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21974746

Group type: EXPERIMENTAL
Intervention: Six weekly sessions of motivational interviewing and cognitive behavioral therapy initiated approximately six weeks prior to release from prison.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Six time matched videos viewed weekly starting about six weeks prior to release (Control group).
Number of subjects: 0
Study: 19303683

Group type: EXPERIMENTAL
Intervention: Highest tertile of uric acid levels
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Continuous increase in uric acid levels (1 mg/dL)
Number of subjects: 838
Study: 17530311

Group type: EXPERIMENTAL
Intervention: On-call counselor intervention
Number of subjects: 482

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 482
Study: 15207409

Group type: EXPERIMENTAL
Intervention: Home care allowance for one year
Number of subjects: 109

Group type: COMPARATOR
Intervention: Traditional geriatric ward care
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Home care allowance
Number of subjects: 109

Group type: COMPARATOR
Intervention: Home hospitalization care
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group of 21 subjects
Number of subjects: 109
Study: 12031560

Group type: EXPERIMENTAL
Intervention: 50-microg misoprostol tablet placed in the posterior vaginal fornix
Number of subjects: 62

Group type: COMPARATOR
Intervention: Expectant management (control group)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Misoprostol (study group)
Number of subjects: 62
Study: 9440664

Group type: EXPERIMENTAL
Intervention: Glyburide 20 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Glipizide GITS 20 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Glipizide GITS
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Glyburide and Glipizide GITS
Number of subjects: 52
Study: 8078203

Group type: EXPERIMENTAL
Intervention: 3 MU IFN daily for 2 weeks and three times weekly for 24 weeks thereafter
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1 MU IFN
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 2775607

Group type: EXPERIMENTAL
Intervention: 30 mg DUP 996
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 361155

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg eight-hourly plus phentolamine 20 mg three-hourly by mouth for three weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 27633773

Group type: EXPERIMENTAL
Intervention: Manipulated morphine-ADER-IMT (60 mg, manipulated)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Manipulated morphine ER (60 mg, manipulated)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Intact morphine-ADER-IMT (60 mg, intact)
Number of subjects: 38
Study: 25817884

Group type: EXPERIMENTAL
Intervention: Ketamine 0.3 mg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Morphine 0.1 mg/kg
Number of subjects: 90
Study: 23660849

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 2029

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2029
Study: 23096008

Group type: EXPERIMENTAL
Intervention: 100 mg L-theanine via capsules
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg L-theanine via green tea
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 50 mg L-theanine via capsules
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 200 mg L-theanine via capsules
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: L-theanine (both treatments)
Number of subjects: 12
Study: 19735580

Group type: COMPARATOR
Intervention: hLF1-11 (0.005, 0.05, 0.5, 5 mg single and multiple intravenous doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: hLF1-11 (5 mg single intravenous dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: hLF1-11
Number of subjects: 0
Study: 17366449

Group type: EXPERIMENTAL
Intervention: Surgical excision
Number of subjects: 100

Group type: COMPARATOR
Intervention: Antibiotic therapy (clarithromycin and rifabutin for at least 12 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Antibiotic therapy
Number of subjects: 100
Study: 15208209

Group type: EXPERIMENTAL
Intervention: Cup feeding (cup/no dummy and cup/dummy)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Dummy use (dummy/no dummy)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Bottle feeding (bottle/no dummy and bottle/dummy)
Number of subjects: 319
Study: 11204097

Group type: EXPERIMENTAL
Intervention: Maximization and progress-monitoring heuristics with lookahead
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extension of the model accounting for insightful moves
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model predictions
Number of subjects: 0
Study: 9916609

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 118
Study: 7830855

Group type: EXPERIMENTAL
Intervention: Prednisone treatment
Number of subjects: 29
Study: 3428343

Group type: EXPERIMENTAL
Intervention: 10 ml saline in the lumbar epidural interspace (n = 5)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 10 ml saline in the thoracic epidural interspace (n = 5)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 2 ml saline in the thoracic interspace (n = 8)
Number of subjects: 23
Study: 29218817

Group type: EXPERIMENTAL
Intervention: CPC decision aid (shared decision making)
Number of subjects: 898

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 898
Study: 27798211

Group type: EXPERIMENTAL
Intervention: Atazanavir/cobicistat (300/150 mg) + daclatasvir (30 mg) once daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Atazanavir/ritonavir (300/100 mg) + daclatasvir (30 mg) once daily
Number of subjects: 16
Study: 26637210

Group type: EXPERIMENTAL
Intervention: Low dose of mycophenolate mofetil (MMF) - 1.03 ± 0.19 g/day at 1 week
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional dose of mycophenolate mofetil (MMF) - 1.48 ± 0.34 g/day at 1 week
Number of subjects: 72

Group type: COMPARATOR
Intervention: ABO compatible KT without rituximab
Number of subjects: 72
Study: 23824420

Group type: EXPERIMENTAL
Intervention: 54 mg genistein daily for 1 year
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 21503807

Group type: EXPERIMENTAL
Intervention: Acetaminophen (APAP) 975 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Ibuprofen (IBU) 800 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Combination of Acetaminophen and Ibuprofen (APAP + IBU)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Ibuprofen (IBU)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Acetaminophen (APAP)
Number of subjects: 79
Study: 19031496

Group type: EXPERIMENTAL
Intervention: Rizatriptan (RI) 10 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Dexamethasone (DE) 4 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Rizatriptan + Dexamethasone (RI+DE)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Dexamethasone + Rizatriptan (DE+RI)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Rizatriptan (RI)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Dexamethasone (DE)
Number of subjects: 35
Study: 17036476

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Sanyinjiao (SP 6) for 3 therapeutic courses, thrice each week, 30 min each time, for 1 month per course.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral administration of nylestriol for 3 months, 2 mg each time, twice each month; medroxyprogesterone added from the third month for 7 days, 6 mg each day.
Number of subjects: 0
Study: 12970830

Group type: EXPERIMENTAL
Intervention: Various treatment-based interventions in stroke rehabilitation
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Five-stage level-of-evidence approach
Number of subjects: 403
Study: 10962655

Group type: EXPERIMENTAL
Intervention: Topical tacalcitol ointment 4 micrograms/g
Number of subjects: 0
Study: 8874908

Group type: EXPERIMENTAL
Intervention: Lidocaine 1% infiltration (Group L)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Normal saline infiltration (Group S)
Number of subjects: 168
Study: 1304807

Group type: EXPERIMENTAL
Intervention: 50 mg/kg chloral hydrate with 25 mg hydroxyzine
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.3 mg/kg temazepam
Number of subjects: 20
Study: 3559574

Group type: EXPERIMENTAL
Intervention: Cemented total hip replacement (THR)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Cemented hemiarthroplasty (UHR‐C)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Noncemented hemiarthroplasty (UHR‐NC)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Overall mortality rate
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Cemented stems
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Uncemented hemiarthroplasties
Number of subjects: 89
Study: 28960597

Group type: EXPERIMENTAL
Intervention: Measured cricoid pressure (CP) using weighing scales to target the ideal CP range (3.060‐4.075 kg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control cricoid pressure where the CP operator was blinded to the amount of CP applied
Number of subjects: 54
Study: 26725406

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Late open-lung (LOL)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Early open-lung (EOL)
Number of subjects: 93
Study: 24776754

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) dosed per m2 BSA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Growth Hormone (GH) dosed per kg BW
Number of subjects: 0
Study: 23169946

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens alone (0.625 mg/d)
Number of subjects: 26747

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (0.625 mg/d conjugated equine estrogens plus 2.5 mg/d medroxyprogesterone acetate)
Number of subjects: 26747

Group type: EXPERIMENTAL
Intervention: Pooled analysis of both groups (E-alone and estrogen plus progestin)
Number of subjects: 26747

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26747
Study: 20130951

Group type: EXPERIMENTAL
Intervention: Cefepime (2 g x 2/day)
Number of subjects: 20
Study: 18580148

Group type: EXPERIMENTAL
Intervention: End-to-side sensate coaptation using the lower lateral cutaneous brachial nerve to the tibial nerve
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (reconstructed without nerve coaptation)
Number of subjects: 30
Study: 16580447

Group type: EXPERIMENTAL
Intervention: Toronto stentless porcine valve
Number of subjects: 160

Group type: COMPARATOR
Intervention: Perimount stented bovine pericardial valve
Number of subjects: 160
Study: 13680555

Group type: EXPERIMENTAL
Intervention: β-blockade treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: β-blocking agents with vasodilating properties
Number of subjects: 0
Study: 10945430

Group type: EXPERIMENTAL
Intervention: Day hospital treatment
Number of subjects: 105

Group type: COMPARATOR
Intervention: Day centre rehabilitation
Number of subjects: 105
Study: 8922515

Group type: EXPERIMENTAL
Intervention: Chemically cured adhesive (Lee Insta‐bond, Lee Pharmaceuticals, EI Monte, Calif.)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Visible light‐cured fluoride‐releasing material (Orthon, Orthon Dental Inc., Victoria, Canada)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Overall bond failure site evaluation
Number of subjects: 50
Study: 1427414

Group type: EXPERIMENTAL
Intervention: 80 mg aspirin/day
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 3882219

Group type: EXPERIMENTAL
Intervention: Active-specific immunotherapy (ASI) with a syngeneic tumor cell:bacillus calmette-Guerin (BCG) vaccine, following surgical resection.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard surgical resection alone (control).
Number of subjects: 40
Study: 30937487

Group type: EXPERIMENTAL
Intervention: Low preoperative mental component score
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Low preoperative physical component score
Number of subjects: 756
Study: 28328548

Group type: EXPERIMENTAL
Intervention: TDF/FTC (once-weekly directly observed therapy)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Daily PrEP
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PrEP regimen adherence
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: TDF/FTC resistance testing
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Next generation sequencing
Number of subjects: 12
Study: 25001954

Group type: EXPERIMENTAL
Intervention: Cortisol (CRT) 40 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23085738

Group type: EXPERIMENTAL
Intervention: 60 mg loading dose (LD) followed by 10 mg maintenance dose (MD) for 10 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 30 mg loading dose (LD) followed by 7.5 mg maintenance dose (MD) for 10 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 30 mg loading dose (LD) followed by 5 mg maintenance dose (MD) for 10 days
Number of subjects: 36
Study: 19637650

Group type: EXPERIMENTAL
Intervention: Bromelain at 0.25% concentration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bromelain at 0% concentration
Number of subjects: 0
Study: 17877825

Group type: EXPERIMENTAL
Intervention: Manual treatment plus home exercise
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Supervised rehabilitative exercise plus home exercise
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Home exercise alone
Number of subjects: 480
Study: 15234276

Group type: EXPERIMENTAL
Intervention: Trypan blue (0.06%) staining
Number of subjects: 43

Group type: COMPARATOR
Intervention: No trypan blue staining
Number of subjects: 43
Study: 11518996

Group type: EXPERIMENTAL
Intervention: Jet-Cutter
Number of subjects: 61

Group type: COMPARATOR
Intervention: CUSA
Number of subjects: 61
Study: 9745105

Group type: EXPERIMENTAL
Intervention: Dietary LCPUFA (arachidonate and docosahexaenoate) in infant formula
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (infants not receiving LCPUFA)
Number of subjects: 22
Study: 7820162

Group type: EXPERIMENTAL
Intervention: Triphasil (ethinyl estradiol/levonorgestrel)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Ortho 7/7/7 (ethinyl estradiol/norethindrone)
Number of subjects: 94
Study: 3342895

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31611333

Group type: EXPERIMENTAL
Intervention: Immediate acupuncture (IA) arm
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist control group (CG)
Number of subjects: 40
Study: 30288674

Group type: EXPERIMENTAL
Intervention: Dietary propionic acid (PA) 200 mg/kg of diet
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Oxytetracycline (OTC) 500 mg/kg of diet
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Combination of PA and OTC
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (basal diet)
Number of subjects: 240
Study: 28501668

Group type: EXPERIMENTAL
Intervention: β-lactam monotherapy
Number of subjects: 1544

Group type: COMPARATOR
Intervention: fluoroquinolone monotherapy
Number of subjects: 1544
Study: 26275160

Group type: EXPERIMENTAL
Intervention: Compensatory scanning training program using horizontal scanning
Number of subjects: 49

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 49
Study: 23262241

Group type: EXPERIMENTAL
Intervention: Early-life stress (ELS) group
Number of subjects: 69

Group type: COMPARATOR
Intervention: Youths without a history of ELS (Control)
Number of subjects: 69
Study: 21395645

Group type: EXPERIMENTAL
Intervention: 400 mg ABZ
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 1500 mg PZQ
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 400 mg ABZ + 1500 mg PZQ
Number of subjects: 9
Study: 19277899

Group type: EXPERIMENTAL
Intervention: DFDBA with AM
Number of subjects: 10

Group type: COMPARATOR
Intervention: BDX with AM
Number of subjects: 10
Study: 17045832

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14, two dried capsules each night for 5 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.75% metronidazole gel, applied vaginally twice a day for 5 days
Number of subjects: 40
Study: 15565824

Group type: EXPERIMENTAL
Intervention: EC plus filgrastim (480 microg or 300 microg daily or every other day, on day 8 through day 14, and 300 microg daily on days 8 and 12 of each chemotherapy course)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: EC plus filgrastim
Number of subjects: 506

Group type: COMPARATOR
Intervention: EC alone
Number of subjects: 506
Study: 10655529

Group type: COMPARATOR
Intervention: Standard oral rehydration therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Rice flour (50 g per liter of oral rehydration solution)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High-amylose maize starch (50 g per liter of oral rehydration solution)
Number of subjects: 48
Study: 9288506

Group type: EXPERIMENTAL
Intervention: Repair of descending thoracic aortic aneurysms with aortobronchial fistulae
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Repair of descending thoracic aortic aneurysms with aortoesophageal fistulae
Number of subjects: 145

Group type: COMPARATOR
Intervention: Repair of descending thoracic aortic aneurysms without fistulae
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Overall mortality at 30 days
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Paraparesis and/or paraplegia
Number of subjects: 145
Study: 8147243

Group type: EXPERIMENTAL
Intervention: Prophylactic Doxycycline (group 1)
Number of subjects: 300

Group type: COMPARATOR
Intervention: No therapy (group 2)
Number of subjects: 300
Study: 3539613

Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (5-ISMN) 60 mg in a controlled release formulation (Durules) given once daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31806540

Group type: EXPERIMENTAL
Intervention: 400 mg olaparib twice daily
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 300 mg olaparib twice daily
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Olaparib (both doses)
Number of subjects: 98
Study: 31248918

Group type: EXPERIMENTAL
Intervention: Oral gabapentin (300‐2700 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Gabapentin and placebo
Number of subjects: 12
Study: 28572159

Group type: EXPERIMENTAL
Intervention: APOL1 high-risk variants (2 risk variants)
Number of subjects: 693

Group type: COMPARATOR
Intervention: APOL1 low-risk variants (0-1 risk variant)
Number of subjects: 693
Study: 25599193

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Number of subjects: 1410

Group type: COMPARATOR
Intervention: Control group (low aerobic exercise)
Number of subjects: 1410
Study: 23725939

Group type: EXPERIMENTAL
Intervention: Combined hands-on training simulation and 20-minute multimedia presentation
Number of subjects: 53

Group type: COMPARATOR
Intervention: Hands-on training simulation alone
Number of subjects: 53
Study: 21533568

Group type: EXPERIMENTAL
Intervention: Intensive integrated intervention
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 210
Study: 18082500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Low-dose MCC-135
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: High-dose MCC-135
Number of subjects: 141
Study: 16530377

Group type: EXPERIMENTAL
Intervention: Preoperative patient education (special educational session and tour of the cardiac surgery unit)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Routine hospital protocol (no preoperative education or tour)
Number of subjects: 110
Study: 12742838

Group type: EXPERIMENTAL
Intervention: 2% dorzolamide hydrochloride (Trusopt 2% eye drops)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.9% saline solution (saline placebo)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Carrier placebo (solution identical to the carrier substance of dorzolamide)
Number of subjects: 20
Study: 11044264

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (Poly Vi‐Sol with iron) three times per week
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation with SP treatment
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation without SP treatment
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 207
Study: 8615485

Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (PCB)
Number of subjects: 40
Study: 1576052

Group type: EXPERIMENTAL
Intervention: 30 mg codeine phosphate
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 30 mg propantheline bromide
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide monohydrochloride
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: All regimens (codeine, propantheline, metoclopramide)
Number of subjects: 6
Study: 6591216

Group type: EXPERIMENTAL
Intervention: nortriptyline
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: femoxetine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 12

Group type: COMPARATOR
Intervention: citalopram
Number of subjects: 12

Group type: COMPARATOR
Intervention: cis-flupenthixol
Number of subjects: 12

Group type: COMPARATOR
Intervention: trans-flupenthixol
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 31370913

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30203006

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 10854

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 10854
Study: 25980843

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.075 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 48